Longevity Biotech is pioneering a new class of therapeutic candidates known as Hybridtides®, which are synthetic peptides designed to enhance drug delivery and efficacy. These Hybridtides® are engineered to be both structurally and digestively stable, incorporating a unique combination of natural and non-natural amino acids. This innovative peptide scaffold allows for the modulation of intracellular signaling pathways, enabling the fine-tuning of biological responses. The company has developed a streamlined, data-driven process for optimizing oral peptide delivery, ensuring that these compounds maintain their functionality while achieving high absorption rates in various biological environments.

The company is actively advancing multiple preclinical programs utilizing the Hybridtide® technology, particularly in the fields of neuroscience and diabetes. One notable candidate, LBT-3627, is being developed as a neuroprotective agent targeting the VPAC 2 receptor, which has shown promise in providing protection against neuroinflammation and neurodegenerative disorders such as Parkinson's Disease. Through collaborations with leading research institutions, Longevity Biotech is focused on understanding the immunomodulatory mechanisms of its compounds, with the goal of translating these findings into effective clinical therapies.

United States

Longevity Biotech, Inc is a company that specializes in breakthrough peptide technology. They are focused on developing a new class of drug candidates called Hybridtides® that deliver unique product profiles. The company is currently in preclinical development.

Longevity Biotech

Company Details